

CHARLES G. MAHAKIAN, M.D.
BOARD CERTIFIED PSYCHIATRIST
6857 WEST CHARLESTON BLVD.
LAS VEGAS, NV 89117
702-258-6437

December 6, 2021

Pharmacy and Therapeutics Committee
State of Nevada Department of Health and Human Services
Division of Health Care Financing and Policy
1100 E. William Street, Suite 101
Carson City, Nevada 89701

Re: December 9, 2021, Meeting; Agenda item 5.f., Discussion and possible adoption of psychotropic agents-antipsychotics-atypical antipsychotics, oral.

To Whom It May Concern:

I understand that Nevada Medicaid will review oral atypical antipsychotics for the Preferred Drug List at the December 9, 2021, Therapeutics Committee meeting. I request that the committee add Caplyta (lumateperone) to the State of Nevada Formulary for schizophrenia.

Caplyta has helped several of my patients with schizophrenia. Medication compliance is a challenge for many of these patients. Some of the major factors of compliance is efficacy and tolerability.

Caplyta offers not only efficacy which was demonstrated statistically superior improvements vs. placebo in symptoms of schizophrenia in 2 clinical trials, as well as safety data similar to placebo. In terms of Metabolic, EPS, prolactin, and weight changes similar to placebo. The simplicity of once-a-day dosing and no titration helps patients adhere to this medication. Please add Caplyta to the State of Nevada Formulary.

Respectfully Submitted,



Charles G. Mahakian M.D.

Nevada License # 5441